127 related articles for article (PubMed ID: 9189138)
1. Extracorporeal whole-blood immunoadsorption enhances radioimmunotargeting of iodine-125-labeled BR96-biotin monoclonal antibody.
Garkavij M; Tennvall J; Strand SE; Sjögren HO; JianQing C; Nilsson R; Isaksson M
J Nucl Med; 1997 Jun; 38(6):895-901. PubMed ID: 9189138
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 125I- and (111)In-labeled monoclonal antibody BR96 for tumor targeting in combination with extracorporeal immunoadsorption.
Garkavij M; Tennvall J; Ohlsson T; Lindgren L; Hindorf C; Sjögren HO; Strand SE
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3059s-3064s. PubMed ID: 10541344
[TBL] [Abstract][Full Text] [Related]
3. Improving tumor-to-normal-tissue ratios of antibodies by extracorporeal immunoadsorption based on the avidin-biotin concept: development of a new treatment strategy applied to monoclonal antibodies murine L6 and chimeric BR96.
Tennvall J; Garkavij M; Chen J; Sjögren HO; Strand SE
Cancer; 1997 Dec; 80(12 Suppl):2411-8. PubMed ID: 9406691
[TBL] [Abstract][Full Text] [Related]
4. Extracorporeal immunoadsorption from whole blood based on the avidin-biotin concept. Evaluation of a new method.
Garkavij M; Tennvall J; Strand SE; Nilsson R; Lindgren L; Chen J; Isaksson M; Eriksson H; Sjögren H
Acta Oncol; 1996; 35(3):309-12. PubMed ID: 8679261
[TBL] [Abstract][Full Text] [Related]
5. Enhanced radioimmunotargeting of 125I-labeled L6-biotin monoclonal antibody (MAb) by combining preload of cold L6 MAb and subsequent immunoadsorption in rats.
Garkavij M; Tennvall J; Strand SE; Norrgren K; Lindgren L; Nilsson R; Sjögren HO
Cancer Res; 1995 Dec; 55(23 Suppl):5874s-5880s. PubMed ID: 7493363
[TBL] [Abstract][Full Text] [Related]
6. Extracorporeal immunoadsorption compared to avidin chase: enhancement of tumor-to-normal tissue ratio for biotinylated rhenium-188-chimeric BR96.
Chen JQ; Strand SE; Tennvall J; Lindgren L; Hindorf C; Sjögren HO
J Nucl Med; 1997 Dec; 38(12):1934-9. PubMed ID: 9430473
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats.
Sjögren HO; Isaksson M; Willner D; Hellström I; Hellström KE; Trail PA
Cancer Res; 1997 Oct; 57(20):4530-6. PubMed ID: 9377565
[TBL] [Abstract][Full Text] [Related]
8. The intratumoral distribution of radiolabeled 177Lu-BR96 monoclonal antibodies changes in relation to tumor histology over time in a syngeneic rat colon carcinoma model.
Örbom A; Eriksson SE; Elgström E; Ohlsson T; Nilsson R; Tennvall J; Strand SE
J Nucl Med; 2013 Aug; 54(8):1404-10. PubMed ID: 23804328
[TBL] [Abstract][Full Text] [Related]
9. Improving radioimmunotargeting of tumors: the impact of preloading unlabeled L6 monoclonal antibody on the biodistribution of 125I-L6 in rats.
Garkavij M; Tennvall J; Strand SE; Norrgren K; Nilsson R; Sjögren HO
J Nucl Biol Med (1991); 1994 Dec; 38(4):594-600. PubMed ID: 7786923
[TBL] [Abstract][Full Text] [Related]
10. Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies.
Gestin JF; Loussouarn A; Bardiès M; Gautherot E; Gruaz-Guyon A; Saï-Maurel C; Barbet J; Curtet C; Chatal JF; Faivre-Chauvet A
J Nucl Med; 2001 Jan; 42(1):146-53. PubMed ID: 11197965
[TBL] [Abstract][Full Text] [Related]
11. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
12. Comparison of copper-67- and iodine-125-labeled anti-CEA monoclonal antibody biodistribution in patients with colorectal tumors.
Delaloye AB; Delaloye B; Buchegger F; Vogel CA; Gillet M; Mach JP; Smith A; Schubiger PA
J Nucl Med; 1997 Jun; 38(6):847-53. PubMed ID: 9189128
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse.
Sato N; Saga T; Sakahara H; Yao Z; Nakamoto Y; Zhang M; Kuroki M; Matsuoka Y; Iida Y; Konishi J
J Nucl Med; 1999 Apr; 40(4):685-92. PubMed ID: 10210230
[TBL] [Abstract][Full Text] [Related]
14. Different toxicity profiles for drug- versus radionuclide-conjugated BR96 monoclonal antibodies in a syngeneic rat colon carcinoma model.
Nilsson R; Eriksson SE; Sjögren HO; Tennvall J
Acta Oncol; 2011 Jun; 50(5):711-8. PubMed ID: 21214493
[TBL] [Abstract][Full Text] [Related]
15. High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: evaluation of toxicity, therapeutic effect, and tumor model.
Mårtensson L; Nilsson R; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
Cancer; 2010 Feb; 116(4 Suppl):1043-52. PubMed ID: 20127949
[TBL] [Abstract][Full Text] [Related]
16. Rapid and specific targeting of 125I-labeled B lymphocyte stimulator to lymphoid tissues and B cell tumors in mice.
Riccobene TA; Miceli RC; Lincoln C; Knight Y; Meadows J; Stabin MG; Sung C
J Nucl Med; 2003 Mar; 44(3):422-33. PubMed ID: 12621010
[TBL] [Abstract][Full Text] [Related]
17. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system.
Goodwin DA; Meares CF; Osen M
J Nucl Med; 1998 Oct; 39(10):1813-8. PubMed ID: 9776294
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo targeting properties of iodine-123- or iodine-131-labeled monoclonal antibody 14C5 in a non-small cell lung cancer and colon carcinoma model.
Burvenich I; Schoonooghe S; Cornelissen B; Blanckaert P; Coene E; Cuvelier C; Mertens N; Slegers G
Clin Cancer Res; 2005 Oct; 11(20):7288-96. PubMed ID: 16243799
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy of carcinoma of colon with [131I]-labeled recombinant chimeric monoclonal antibodies to carcinoembryonic antigen.
Lu QJ; Bian GX; Chen YY; Zhang M; Guo SM; Wen LQ
Acta Pharmacol Sin; 2005 Oct; 26(10):1259-64. PubMed ID: 16174444
[TBL] [Abstract][Full Text] [Related]
20. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
